Saturday, July 11, 2026

pharma · NSCLC

Formycon

Formycon AG is a pharma organization headquartered in Planegg, DE. Primary therapeutic focus areas include NSCLC. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from

Planegg, DE HQ
2012 Founded
178 Employees
EMA registrant Type
Company details
Status
Public
HQ
Planegg, DE
Founded
2012
Employees
178
Programs
2
Drugs
4
Patents
0
Clinical program

FYB206-C3-02

Phase 3 · small molecule · NSCLC

FYB206-C3-02 for NSCLC is a Phase 3 program (small_molecule) at Formycon AG with 1 ClinicalTrials.gov record(s).

← All Formycon AG projects Phase 3 small molecule active

Internal code FYB206-C3-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Formycon AG
Phase
Phase 3
Modality
small_molecule
Indication
NSCLC
Status
active
Trials
1